macro

Vanda settles patent dispute with MSN, clearing generic HETLIOZ LQ entry for 2040

Vanda Pharmaceuticals signed a settlement and license deal with MSN that sets the timing for a generic HETLIOZ LQ launch in the US.

the same feed is available to bots and dashboards through the api. connect the api →

what happened

Vanda Pharmaceuticals has signed a settlement and license agreement with MSN that resolves patent litigation over MSN's proposed generic version of HETLIOZ LQ. Under the non-exclusive license, which carries no royalties, US sales can generally begin in the first quarter of 2040, though an earlier entry is possible in certain circumstances. The deal also provides for the litigation to be dismissed, along with a consent judgment and injunction that remain subject to court approval. The details come from TradingView, based on documents filed with the SEC.

why it matters

For markets the story is mostly company-specific: the deal sets an approximate date for a cheaper competitor to HETLIOZ LQ and reduces some uncertainty about Vanda's future revenue, but its broader market impact is limited.

tags

instruments

Vanda Pharmaceuticals

sources

  1. Vanda Pharmaceuticals Settles MSN Patent Dispute, Licensing Generic HETLIOZ LQ Entry by 2040 — TradingView, 20 November 2026 at 12:13 UTC

prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.

alerts on your topics, the morning digest and the api — in your account.

get stories in real time ↗